Truly human antibody therapeutics.
Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.
Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!
REPTOR™
Next-Gen Sequencing Hybridoma
REPTOR™
Next-Gen Sequencing Bulk B Cells
REPTOR™
Next-Gen Sequencing Hit Expansion
REPTOR™
Next-Gen Sequencing Display Library
ALICANTO®
Rabbit Monoclonal Antibody Discovery
ALICANTO®
Single Domain (VHH) Antibody Discovery
ALICANTO®
Human Antibody Discovery
VALENS™
Protein Sequence Confirmation
VALENS™
Antibody Protein Sequencing
Our partners’ success means everything to us
I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.
I would strongly recommend the services, Valens and Reptor, from Abterra Bio. Not only were the individuals extremely helpful throughout the development of my project, but they were always available to answer any questions I had throughout the project. Best of all, Abterra provided high-quality sequences with a rapid turnover which allowed my lab to continue our research with little delay.
Latest News
Problem Solvers by Nature
"When @necastellana began applying algorithms for protein analysis, she realized that most methods did not utilize the power of the human body’s adaptive immune system." Read about how to unlock the power of the human immune system using bioinformatics.
Alicanto Innovative New Product Award Finalist
We’re thrilled to announce that Alicanto® was selected as a finalist in CONNECT’s Most Innovative New Product Awards. CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences sectors,...
Phase 1 SBIR Award-Quorum Cloud
Quorum Cloud® is a computational platform that organizes tandem MS data into molecular networks. Molecular networks connect related compounds that differ by a mutation, modification, or adduct. Quorum Cloud® increases NP compound annotations compared to previous...
Scientific Updates
De Novo Antibody Sequencing Case Study
Abterra Bio uses bioinformatics and mass spectrometry to reconstructs the full amino acid sequence of both antibody chains. We’ve successfully sequenced human, mouse, rat, hamster, rabbit, and llama antibodies. This approach can be applied across any species and...
New Publication Reveals Ebolavirus-Neutralizing Monoclonal Antibodies
Abterra Biosciences, together with VUMC Vaccine Center, Mapp Bio, PNNL, UTMB Health, Ragon Institute, Integral Molecular, and La Jolla Institute, recently published a paper describing the discovery of Ebolavirus-neutralizing antibodies from convalescent plasma.Read...
Immune Repertoire Sequencing in Human
Immune repertoire sequencing enables deeper understanding of the adaptive immune response [1]. Abterra Biosciences has developed Reptor™, a flexible immune repertoire sequencing and analysis service. In this study, we analyzed the B-cell receptor (BCR) repertoire...
Clonal Hit-Expansion Case Study
Abterra Bio uses next-generation sequencing to mine the clonal lineage of serum-identified antibodies. This method rescues relatives of hits that are within a clone and increases diversity in your antibody discovery campaign. Contact us to learn more about how our...
Every day, we strive to help our partners and collaborators push the boundaries of their science.
